Bintrafusp alfa (a PD-L1/TGF-β BSAB) has shown certain antitumor activity in patients with NPC who have failed platinum-based chemotherapy (ORR, 23.7%; 1-year OS rate, 57.5%). The gene discussed is CD274; the disease is nasopharyngeal carcinoma.